Clinical lung cancer最新文献

{"title":"Rapid Lorlatinib Response in Lung Adenocarcinoma With a Novel Y Chromosome Intergenic ALK Fusion: A Case Report","authors":"Jin-Ming Chen,&nbsp;Yi-Fan Kang,&nbsp;Yue-Can Zeng,&nbsp;Jing-Ru Luo,&nbsp;Shu Lin,&nbsp;Wen-Jun Tang","doi":"10.1016/j.cllc.2026.09.002","DOIUrl":"10.1016/j.cllc.2026.09.002","url":null,"abstract":"<div><h3>Clinical Practice Points</h3><div><ul><li><span>•</span><span><div>Unexplained rapid disease progression in young, never-smoker patients with lung adenocarcinoma warrants comprehensive large-panel DNA-NGS to detect atypical actionable driver mutations, especially when routine small-panel testing returns negative.</div></span></li><li><span>•</span><span><div>Atypical, focal, or weak ALK immunohistochemistry (IHC) signals should not be readily dismissed as artifacts; they can serve as early indicators of complex, non-canonical intergenic fusions resulting from cross-chromosomal genomic rearrangements.</div></span></li><li><span>•</span><span><div>The third-generation ALK inhibitor lorlatinib demonstrates profound systemic and intracranial efficacy against non-canonical Y-chromosome intergenic-ALK fusions, highlighting its role as a potent therapeutic option for atypical ALK variants.</div></span></li></ul></div></div><div><ul><li><span>•</span><span><div>Unexplained rapid disease progression in young, never-smoker patients with lung adenocarcinoma warrants comprehensive large-panel DNA-NGS to detect atypical actionable driver mutations, especially when routine small-panel testing returns negative.</div></span></li><li><span>•</span><span><div>Atypical, focal, or weak ALK immunohistochemistry (IHC) signals should not be readily dismissed as artifacts; they can serve as early indicators of complex, non-canonical intergenic fusions resulting from cross-chromosomal genomic rearrangements.</div></span></li><li><span>•</span><span><div>The third-generation ALK inhibitor lorlatinib demonstrates profound systemic and intracranial efficacy against non-canonical Y-chromosome intergenic-ALK fusions, highlighting its role as a potent therapeutic option for atypical ALK variants.</div></span></li></ul></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"27 8","pages":"Pages 69-73"},"PeriodicalIF":3.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MET Testing and Treatment Sequencing After Disease Progression on First-Line Osimertinib in Patients With EGFR-Mutated Advanced NSCLC and Acquired MET Overexpression and/or Amplification: A Global Real-World Study","authors":"Julia Rotow,&nbsp;Umberto Malapelle,&nbsp;Daniel Cuadras,&nbsp;Núria Lara,&nbsp;Noelia Caro,&nbsp;Montserrat Roset,&nbsp;Montse Pedros,&nbsp;Yacob Pinchevsky,&nbsp;YongJin Kim","doi":"10.1016/j.cllc.2026.08.011","DOIUrl":"10.1016/j.cllc.2026.08.011","url":null,"abstract":"<div><h3>Background</h3><div>Given the potential benefit of MET-tyrosine kinase inhibitors (TKIs) after progression on osimertinib in <em>EGFR</em>-mutated advanced NSCLC, evaluating real-world biomarker testing and treatment sequencing is important. We report findings from a global, direct-to-physician, survey-based chart review.</div></div><div><h3>Patients and Methods</h3><div>Physicians treating NSCLC were surveyed regarding rebiopsy and MET testing practices and awareness of MET overexpression and/or amplification (OverExp/Amp) cutoff levels. Biomarker testing, MET OverExp/Amp quantification and treatment sequencing were assessed in patients with <em>EGFR</em>-mutated advanced NSCLC with acquired MET OverExp/Amp after progression on first-line osimertinib, who received second-line treatment between January 2018 and December 2023 (data cutoff: April 8, 2025).</div></div><div><h3>Results</h3><div>Among 280 physicians, rebiopsy practices varied; the most commonly reported MET testing method was NGS (78%), followed by IHC (11%) and FISH (11%). Understanding of MET OverExp/Amp cutoff levels varied, with 35%-47% of physicians unaware of appropriate cutoffs. Among 367 patients (94% with <em>MET</em> Amp), MET alterations were mostly detected through tissue-based (58%) versus liquid-based tests (31%) or both (11%). MET alterations were detected using NGS (77%), then PCR (10%), IHC (10%), and FISH (4%). In 257 patients with MET cutoff data available, most <em>MET</em> Amp had gene copy numbers ≥6 (88%). MET-TKIs (29%) and EGFR-TKIs (24%) were the most common second-line treatments, followed by chemotherapy (20%). Of 193 patients with high MET levels, most received targeted treatments (MET-TKI 35%, EGFR-TKI 23%).</div></div><div><h3>Conclusion</h3><div>Rebiopsy practices and knowledge of MET OverExp/Amp cutoffs varied among physicians. IHC/FISH were underutilized; however, their use should be encouraged for optimal patient identification and treatment selection.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"27 8","pages":"Pages 74-86"},"PeriodicalIF":3.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated Genomic and Immune Profiling of Early Onset Lung Cancer in East Asians Reveals a Distinct Molecular Architecture","authors":"Jianhua Wang,&nbsp;Zhongyu Lu,&nbsp;Minghui Ge,&nbsp;Xing Zhang,&nbsp;Dongsheng Chen,&nbsp;Xiaohong Peng","doi":"10.1016/j.cllc.2026.07.009","DOIUrl":"10.1016/j.cllc.2026.07.009","url":null,"abstract":"<div><h3>Background</h3><div>The age cut-off for early-onset lung cancer (EOLC) varies across studies (40-50 years). Here, we define EOLC as diagnosis at ≤ 40 years, a threshold identifying a subgroup with distinct clinical characteristics. However, whether EOLC differs fundamentally from late-onset lung cancer (LOLC) at the molecular level and represents a distinct subtype requiring different management remains unclear.</div></div><div><h3>Methods</h3><div>This integrated analysis included genomic and immune profiling data from 8,021 lung cancer patients, comprising 302 EOLC and 7,719 LOLC cases. Using targeted sequencing, we assessed somatic and germline alterations, mutational signatures, and immune biomarkers including tumor mutational burden (TMB), MSI status, and PD-L1 expression.</div></div><div><h3>Results</h3><div>EOLC patients were more often female, had adenocarcinoma, and earlier-stage disease. Molecular profiling revealed significant enrichment of ERBB2 mutations in EOLC, while KRAS, TP53, and MET mutations were more common in LOLC. Mutational signature analysis indicated tobacco-related signatures predominated in LOLC, whereas endogenous processes contributed more substantially in EOLC. Germline analysis showed a higher burden of pathogenic variants in EOLC (14.57% vs. 8.93%, <em>P</em> &lt; .01), with TP53 and BRCA1 being particularly prominent. Immunologically, LOLC tumors exhibited higher TMB and PD-L1 positivity.</div></div><div><h3>Conclusion</h3><div>Integrated profiling establishes EOLC as a distinct molecular subtype, defined by a unique triad: an ERBB2-driven somatic profile, germline susceptibility in DNA damage response pathways, and an endogenous mutagenic process within a low-TMB microenvironment. The findings are specific to the selected threshold and should be interpreted accordingly, while elucidating EOLC pathogenesis and supporting age-specific management strategies.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"27 7","pages":"Pages 129-135"},"PeriodicalIF":3.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and Functional Factors Associated With Radiation Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors: A Retrospective Cohort Study","authors":"Anissa Boutahir,&nbsp;Leila Bouazzi,&nbsp;Coralie Barbe,&nbsp;Gaetan Deslee,&nbsp;Maxime Dewolf,&nbsp;Leila Ettalhaoui,&nbsp;Camille Invernizzi,&nbsp;Amelie Lemoine,&nbsp;Yacine Meziane,&nbsp;Alexandre Roque,&nbsp;Julien Ancel,&nbsp;Arnaud Beddok","doi":"10.1016/j.cllc.2026.04.007","DOIUrl":"10.1016/j.cllc.2026.04.007","url":null,"abstract":"<div><h3>Introduction</h3><div>To identify associated factors for radiation pneumonitis (RP) after stereotactic body radiation therapy (SBRT), focusing on pretreatment pulmonary function parameters and baseline clinical characteristics.</div></div><div><h3>Materials and Methods</h3><div>Patients with primary or secondary lung tumors who underwent pulmonary function tests (PFTs) before SBRT were retrospectively analyzed. Clinical and imaging follow-up was conducted at 6 weeks, 6, 12, and 18 months post-treatment. RP diagnosis was based on clinical symptoms, bronchoscopic findings, radiological abnormalities, and their evolution over time. RP severity was graded according to common terminology criteria for adverse events v5.0 criteria. Associated factors were assessed using univariate and multivariate logistic regression analyses.</div></div><div><h3>Results</h3><div>Between November 2016 and October 2023, 68 patients who received SBRT for lung tumors with available pretreatment PFTs were included. Median age was 70 years; 63.2% were male; 54.4% had chronic obstructive pulmonary disease, and 85.2% had primary lung cancer. RP occurred in 47 patients (69.1%), including 25% with grade 2 and 9.1% with grade 3 toxicity. In multivariate analysis, lower age (odd ratio [OR] 0.87 [0.77-0.98]; <em>P</em> = .02), higher total lung capacity (OR 1.13 [1.04-1.24]; <em>P</em> = .006), and higher diffusing capacity of the lung for carbon monoxide (OR 1.05 [1.01-1.10]; <em>P</em> = .01) were significantly associated with RP. Previous chemotherapy exposure was a protective factor for the occurrence of clinically significant RP (grade ≥ 2) (<em>P</em> = .02).</div></div><div><h3>Conclusion</h3><div>Age, diffusing capacity of the lung for carbon monoxide, and total lung capacity were identified as significant associated factors for RP after lung SBRT. Incorporating clinical, dosimetric, and functional respiratory parameters into a multifactorial predictive model could optimize patient selection and risk stratification.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"27 6","pages":"Pages 83-90"},"PeriodicalIF":3.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148155577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma","authors":"Giulia Pasello,&nbsp;Daniela Scattolin,&nbsp;Eleonora Faccioli,&nbsp;Paolo Andrea Zucali,&nbsp;Giuseppe Marulli,&nbsp;Federica Grosso,&nbsp;Giovanni Luca Ceresoli,&nbsp;Marcello Tiseo,&nbsp;Alessandra Bearz,&nbsp;Fabiana Letizia Cecere,&nbsp;Luana Calabrò,&nbsp;Francesco Callegarin,&nbsp;Paola Del Bianco,&nbsp;Gian Luca De Salvo,&nbsp;Federica Pezzuto,&nbsp;Fiorella Calabrese,&nbsp;Valentina Guarneri,&nbsp;Andrea Dell’Amore,&nbsp;Federico Rea","doi":"10.1016/j.cllc.2026.05.004","DOIUrl":"10.1016/j.cllc.2026.05.004","url":null,"abstract":"<div><div>Pleural mesothelioma (PM) is a rare asbestos-related malignancy characterized by complex diagnosis and poor prognosis, with survival strongly influenced by histological subtype and eligibility for a multimodality approach, reserved for highly selected patients. While platinum–pemetrexed chemotherapy or the combination of ipilimumab plus nivolumab represent standard first-line options for unresectable disease, pembrolizumab combined with platinum–pemetrexed has demonstrated improved survival in advanced PM (IND227/Keynote483 trial). In resectable PM, multimodality treatment including surgery and chemotherapy remains preferred, yet pathological complete response (pCR) rates remain low at approximately 5%, and the role of perioperative immunotherapy is still poorly defined. CHIMERA is a prospective, open-label, multicenter phase II single-arm trial evaluating neoadjuvant pembrolizumab combined with platinum–pemetrexed chemotherapy followed by surgery and adjuvant pembrolizumab in patients with treatment-naïve, resectable stage I–IIIA epithelioid or biphasic PM. Patients receive three cycles of neoadjuvant pembrolizumab plus cisplatin or carboplatin and pemetrexed every three weeks, followed by centralized pleurectomy/decortication or extended pleurectomy/decortication in two high-volume referral centers, and subsequently 14 cycles of adjuvant pembrolizumab. The primary endpoint is pCR, with secondary endpoints including major pathological response, objective response rate, event-free survival, overall survival, treatment feasibility, and safety; translational tissue- and blood-based biomarker analyses are planned. The study is powered to detect an increase in pCR from 5% to 18%, requiring 40 patients to account for potential dropouts. By focusing on pathological efficacy within a standardized multimodality framework, CHIMERA aims to clarify the role of perioperative chemo-immunotherapy and to improve outcomes for patients with resectable PM.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"27 6","pages":"Pages 31-35"},"PeriodicalIF":3.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148270681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and Clinical Outcomes of De Novo and Acquired Uncommon Compound EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer: A Brief Report","authors":"Kevin Lu,&nbsp;Sandip P. Patel,&nbsp;Tali Azenkot","doi":"10.1016/j.cllc.2026.05.005","DOIUrl":"10.1016/j.cllc.2026.05.005","url":null,"abstract":"<div><h3>Introduction</h3><div>The optimal treatment of uncommon, compound <em>EGFR</em>-mutated NSCLC is poorly defined due to heterogeneous responses to targeted therapies.</div></div><div><h3>Patients and Methods</h3><div>We retrospectively reviewed patient characteristics and treatment outcomes from cohorts of advanced <em>EGFR</em>-mutated NSCLC patients at UC San Diego Health and the American Association of Cancer Research GENIE database.</div></div><div><h3>Results</h3><div>In our institutional cohort, L858R-mutated patients were significantly more likely to have a <em>de novo</em> compound mutation than those with exon19del (24/159 [15%] vs. 4/228 [2%], <em>P</em> &lt; .01). Conversely, acquired C797S mutations more often co-occurred with exon19del after osimertinib progression compared to L858R (23/113 [20%] vs. 6/89 [7%], <em>P</em> &lt; .01). In the GENIE database, 88% of patients with S768I mutations had an additional <em>EGFR</em> co-mutation, most commonly G719X. Osimertinib time to treatment failure (TTF) varied notably in our institutional cohort: patients with co-mutated G719X/L861Q exhibited a median TTF &gt; 13 months, and those with G719X alone had a median TTF &lt; 7 months.</div></div><div><h3>Conclusion</h3><div>Our findings demonstrate that compound <em>EGFR</em> mutations comprise distinct subgroups with unique clinical characteristics and different responses to targeted therapy. For example, osimertinib may be a viable treatment for patients with compound G719X/L861Q mutations. Further characterization of these heterogeneous subgroups is warranted for identifying optimal treatment strategies as novel targeted agents emerge.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"27 6","pages":"Pages 64-67"},"PeriodicalIF":3.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148283425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durvalumab After Chemoradiotherapy for Locally Advanced NSCLC: A Real-World Analysis Using a Nationwide Claims Database in Japan","authors":"Kazuya Takeda,&nbsp;Takaya Yamamoto,&nbsp;Rei Umezawa,&nbsp;Noriyoshi Takahashi,&nbsp;Shinsaku Okuda,&nbsp;Keiichi Jingu","doi":"10.1016/j.cllc.2026.05.010","DOIUrl":"10.1016/j.cllc.2026.05.010","url":null,"abstract":"<div><h3>Background</h3><div>Durvalumab consolidation therapy after chemoradiotherapy (CRT) for locally advanced non-small cell lung cancer (NSCLC) is an established standard of care. However, real-world data from claims databases, which capture a broad clinical landscape, are lacking in Asia. This study aimed to characterize real-world treatment patterns and clinical outcomes using a nationwide claims database in Japan.</div></div><div><h3>Patients and Methods</h3><div>Patients who received durvalumab after definitive CRT for NSCLC between 2018 and 2024 were identified from the DeSC database. Overall survival (OS) was estimated using the Kaplan–Meier method. Radiation pneumonitis requiring steroid treatment was estimated using the cumulative incidence function with death as a competing risk.</div></div><div><h3>Results</h3><div>A total of 1439 patients were identified, and the median age was 73.6 years. The median durvalumab treatment duration was 5.3 months, and treatment completion rates (≥ 10 and ≥ 11 months) were 32.2% and 26.3%, respectively. The median OS was 48.4 months (95% CI, 42.1-57.4 months). The 12-month cumulative incidence of pneumonitis requiring steroid treatment was 19.4% (95% CI, 17.3-21.6%). In multivariable analysis, increasing age, shorter CRT-to-durvalumab interval, pre-existing pneumonitis diagnosis, and respiratory motion management fee were associated with increased pneumonitis risk, whereas the use of intensity-modulated radiotherapy was associated with reduced risk. Among 280 patients who developed pneumonitis, durvalumab rechallenge was administered in 37.5%.</div></div><div><h3>Conclusion</h3><div>In this nationwide claims database study, we characterized the clinical practice of CRT with durvalumab treatment and the clinical outcomes in Japan. These real-world findings from Asia complement existing evidence and may inform treatment optimization for durvalumab after CRT.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"27 6","pages":"Pages 43-49"},"PeriodicalIF":3.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148276317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosimetric Predictors of Radiation Pneumonitis for Stage III NSCLC Treated With Neoadjuvant Immuno-chemotherapy and Definitive Chemoradiation: A Multi-institutional Analysis","authors":"Yang Liu,&nbsp;YunXiang Qi,&nbsp;Wenyan Pan,&nbsp;Wei Bai,&nbsp;Yaoxin Chen,&nbsp;Hao Zhou,&nbsp;Chaoyuan Liu,&nbsp;Pan Xi,&nbsp;Xiaoyan Li,&nbsp;Liangxue Hou,&nbsp;Xuan Tao,&nbsp;Yaoxiong Xia,&nbsp;Xi Zhang,&nbsp;Zewen Song","doi":"10.1016/j.cllc.2026.05.008","DOIUrl":"10.1016/j.cllc.2026.05.008","url":null,"abstract":"<div><h3>Background</h3><div>For patients with unresectable stage III non–small cell lung cancer (NSCLC) treated with neoadjuvant immuno-chemotherapy followed by definitive radiotherapy, the risk of radiation pneumonitis (RP) may be elevated. This multicenter study aimed to validate established dose-volume predictors in this specific treatment context.</div></div><div><h3>Methods</h3><div>We analyzed 372 stage III NSCLC patients from 9 institutions who received neoadjuvant (NEO) or adjuvant immunotherapy. RP was graded per CTCAE v5.0. Univariable and multivariable logistic regression identified factors associated with grade ≥ 2 (RP2) and grade ≥ 3 (RP3) RP within the NEO cohort. Optimized dosimetric thresholds were derived using ROC curves.</div></div><div><h3>Results</h3><div>In the NEO cohort, multivariable analysis showed lung V20 independently predicted RP2 (odd ratio [OR]: 1.09, 95% confidence interval [CI]: 1.05-1.14, <em>P</em> &lt; .001), while mean lung dose (MLD) independently predicted RP3 (OR: 1.11, 95% CI, 1.02-1.22, <em>P</em> = .018). The optimal cutoffs were V20 ≤ 24% and MLD ≤ 14 Gy. A composite constraint (V20 ≤ 24% and MLD ≤ 14 Gy) significantly reduced RP2 (20.8% vs. 49.5%) and RP3 (8.2% vs. 23.1%) incidence compared to non-compliant plans. This new constraint showed significant net reclassification improvement for RP2 (NRI = 17.4%, <em>P</em> = .027) over conventional criteria (V20 ≤ 35%, MLD ≤ 20 Gy).</div></div><div><h3>Conclusion</h3><div>Stricter dosimetric constraints (V20 ≤ 24%; MLD ≤ 14 Gy) are critical for mitigating RP risk in stage III NSCLC patients treated with neoadjuvant immuno-chemotherapy and radiotherapy, providing tailored guidance for planning in the immunotherapy era.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"27 6","pages":"Pages 50-57"},"PeriodicalIF":3.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148276252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of Lung Cancer Risk Prediction Models in the Singapore Chinese Population","authors":"Yah Ru Juang,&nbsp;Wenjia Chen,&nbsp;Alvin Jing Hui Ng,&nbsp;Xueling Sim,&nbsp;Darren Wan-Teck Lim,&nbsp;Jian-Min Yuan,&nbsp;Adeline Seow,&nbsp;Wei Jie Seow","doi":"10.1016/j.cllc.2026.04.014","DOIUrl":"10.1016/j.cllc.2026.04.014","url":null,"abstract":"<div><h3>Background</h3><div>Despite effective screening technologies for smokers, lung cancer is often diagnosed late, especially among never-smokers who fall outside current screening guidelines. We developed 10-year risk prediction models for sex and smoking subgroups to support more precise identification of high-risk individuals in clinical settings.</div></div><div><h3>Patients and Methods</h3><div>Using the Singapore Chinese Health Study (n = 63,187; recruitment period: 1993-1998), we developed a robust Cox regression model to predict 10-year lung cancer risk. Essential predictors were identified from sociodemographic, smoking-related, environmental exposure, reproductive, and dietary factors using Elastic Net regularization with 10-fold cross-validation. External validation was conducted using the Singapore Multi-Ethnic Cohort (n = 12,944; recruitment period: 2004-2010). Sex- and smoking-specific risk models were developed using the same approach.</div></div><div><h3>Results</h3><div>The overall risk model demonstrated strong discrimination and calibration on external validation (C-index = 0.821; 95% CI, 0.738-0.895). Ranked by relative importance, key predictors included age, smoking exposure (pack-years, smoking status), body mass index, education, sex, environmental tobacco smoke exposure, and dietary factors (tea and fruit consumption). The ever-smoker risk model included age, body mass index, pack-years, education, and weekly fruit consumption (C-index = 0.734), while the never-smoker risk model included age, sex, environmental tobacco smoke exposure, personal cancer history, and allergic rhinitis (C-index = 0.702). Sex-specific risk models showed good discrimination (male C-index = 0.785; female C-index = 0.769), with the female risk model influenced by reproductive and medical history factors.</div></div><div><h3>Conclusion</h3><div>These subgroup-specific risk models provide additional insights into lung cancer risk assessment beyond smoking history and, with further real-world evaluation, may support more tailored risk stratification in Singapore’s clinical settings.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"27 6","pages":"Pages 91-101"},"PeriodicalIF":3.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148154918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete Spontaneous Regression of Lung Adenocarcinoma With No Residual Malignancy After Surgical Resection: A Case Report","authors":"Anders Näslund,&nbsp;Hans Brunnström,&nbsp;Jesper Andreasson,&nbsp;Marija Karadzovska-Kotevska,&nbsp;Hamid Akbarshahi","doi":"10.1016/j.cllc.2026.05.007","DOIUrl":"10.1016/j.cllc.2026.05.007","url":null,"abstract":"","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"27 6","pages":"Pages 27-30"},"PeriodicalIF":3.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148263620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}